In 2014, initial discussions between Genea Biomedx and Merck Fertility Technologies identified the potential which could be achieved through collaboration. From this the concept of ARTinnovations was born.
We’ve only just started, but the future is already looking bright.
The world is full of incredibly gifted scientists. And we know that in this collective consciousness, lies the next big idea for fertility. Yet we also know many people often think their idea is too hard to get off the ground or they lack the support to develop their innovation.
This is why Genea Biomedx and Merck Fertility Technologies have come together to form ARTinnovations. ARTinnovations is an incubator for ideas and innovations for fertility treatment and technologies. ARTinnovations provides the support and know-how to develop ideas so that they take root and grow into better outcomes for patients. Together, through the collaboration, we aim to progress fertility treatments and technologies to the next level.
Genea is a fertility pioneer, researching, developing and introducing breakthrough techniques and technologies in assisted reproductive treatment for almost 30 years. The group is responsible for advances in fertility treatment which virtually doubled IVF success rates in the mid-nineties and continues to improve outcomes today through innovative and world first discoveries and technologies. Genea is a strongly interconnected group of three companies:
Genea Fertility has clinics across Australia and in New Zealand and Thailand and offers patients an almost 40 per cent greater chance of taking home a healthy baby compared to the average of all other Australian and New Zealand clinics combined*.
Genea Biomedx creates and manufactures practical, accessible and precise fertility technologies that help standardise and automate fertility treatment. Its unique relationship with Genea Fertility means that Genea Biomedx is a manufacturer that truly understands the customers’ perspective. As a result Genea Biomedx has developed the world’s first automated vitrification instrument, and has other projects well advanced in the product pipeline.
Genea Biocells develops unique disease-specific and unaffected human pluripotent stem cell lines, differentiated cells, including the first robust skeletal muscle differentiation platform; culture media and small molecule libraries for use in research, drug development and cell therapy. Genea Biocells partners with scientists in industry and academia to advance innovative projects using chemical biology and stem cell-driven approaches.
*According to age-standardised analysis of the latest available data (2013) released September 2015 from the Australian and New Zealand Assisted Reproduction Database (ANZARD) and based on live births per embryo transfer for women using their own eggs.
Merck is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. Generating sales of around € 12.8 billion in 2015. Around 50,000 Merck employees work in 66 countries to improve the quality of life for patients, to foster the success of customers and to help meet global challenges from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions.
Merck is the world’s oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70% interest, the founding family remains the majority owner of the company to this day. Merck, Darmstadt, Germany, holds the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.
If you would like to learn more about ARTinnovations, please email us at info@ARTinnovations.org